<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; GPhA</title>
	<atom:link href="http://www.tapanray.in/tag/gpha/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Scandalizing Biosimilar Drugs With Safety Concerns</title>
		<link>http://www.tapanray.in/scandalizing-biosimilar-drugs-with-safety-concerns/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=scandalizing-biosimilar-drugs-with-safety-concerns</link>
		<comments>http://www.tapanray.in/scandalizing-biosimilar-drugs-with-safety-concerns/#comments</comments>
		<pubDate>Mon, 25 Aug 2014 00:00:20 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[12]]></category>
		<category><![CDATA[badmouthing]]></category>
		<category><![CDATA[Bio]]></category>
		<category><![CDATA[Biologic]]></category>
		<category><![CDATA[biosimilar]]></category>
		<category><![CDATA[chain]]></category>
		<category><![CDATA[concerns]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[EMA]]></category>
		<category><![CDATA[Exclusivity]]></category>
		<category><![CDATA[generic]]></category>
		<category><![CDATA[GPhA]]></category>
		<category><![CDATA[Hamburg]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[INN]]></category>
		<category><![CDATA[Investor]]></category>
		<category><![CDATA[proposal]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Safety]]></category>
		<category><![CDATA[scandalizing]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[USFDA]]></category>
		<category><![CDATA[value]]></category>
		<category><![CDATA[WHO]]></category>
		<category><![CDATA[Year]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=5772</guid>
		<description><![CDATA[With the patent expiry of exorbitantly priced biologic medicines, introduction of biosimilar drugs are expected to improve their access to millions of patients across the world, saving billions of dollars in healthcare costs in the subsequent years. According to an &#8230; <a href="http://www.tapanray.in/scandalizing-biosimilar-drugs-with-safety-concerns/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/scandalizing-biosimilar-drugs-with-safety-concerns/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
